Three injectable therapies now dominate the weight loss field, each targeting gut hormones in fundamentally different ways. Semaglutide works on a single pathway. Tirzepatide adds a second. Retatrutide adds a third. The differences sound subtle in theory, but the clinical data tells a more dramatic story.

What Makes These Drugs Different: The Receptor Story

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone released from the gut after eating. GLP-1 sends satiety signals to the brain and slows stomach emptying. The result is reduced hunger and fewer calories consumed. This single-mechanism approach produced a 14.9% mean weight loss in the landmark STEP 1 trial at 68 weeks [5].

Tirzepatide adds a second target. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP complements GLP-1 by enhancing insulin sensitivity and further suppressing appetite through separate neural pathways. The dual mechanism produced substantially higher weight loss: 20.9% mean at the 15 mg dose in SURMOUNT-1 [4]. In the SURPASS-2 head-to-head trial, tirzepatide 15 mg reduced HbA1c by 2.58% compared to semaglutide 1 mg's 2.24%, and weight loss was 12.4 kg versus 6.2 kg [4]. The addition of GIP was not cosmetic.

Retatrutide goes further. It is a triple agonist, targeting GLP-1, GIP, and the glucagon receptor. Glucagon activation promotes fat burning and increases energy expenditure, not just calorie reduction. This three-pronged biological approach produced results that surprised even researchers: 28.7% mean weight loss at 68 weeks in the TRIUMPH-4 Phase 3 trial [1]. That figure translates to 71.2 lbs lost from a baseline body weight of 248.5 lbs [1].

The Efficacy Data Side by Side

Direct comparison requires caution since these drugs were tested in different populations at different times. The broad evidence base, however, permits a structured look at outcomes.

Retatrutide at 12 mg achieved 28.7% mean weight loss at 68 weeks in TRIUMPH-4 [1]. The 9 mg dose produced 26.4% mean weight loss, or 64.2 lbs [1]. On placebo, participants lost 2.1% of body weight, or 4.6 lbs [1].

Tirzepatide at 15 mg achieved 20.9% mean weight loss at 72 weeks in SURMOUNT-1, equivalent to 24.0 kg or roughly 52.9 lbs [4]. In SURMOUNT-2, involving participants with type 2 diabetes, the same dose produced 22.5% mean weight loss at 72 weeks [4]. Extended 176-week data from SURMOUNT-4 showed tirzepatide maintaining 22.9% mean weight loss, with participants who switched from placebo to tirzepatide losing 17.7% by week 176 [3].

Semaglutide at 2.4 mg achieved 14.9% mean weight loss at 68 weeks in STEP 1 [5]. One-third of participants lost 20% or more of their body weight [5]. Discontinuation due to adverse events occurred in 7.0% of participants on semaglutide versus 3.1% on placebo [5].

The magnitude of difference is not incremental. Retatrutide's 28.7% substantially exceeds tirzepatide's roughly 21%, which substantially exceeds semaglutide's roughly 15%. The dose-response curve appears steeper with each added receptor mechanism.

Beyond the Scale: Metabolic and Pain Outcomes

Weight loss is not the only clinically meaningful endpoint. TRIUMPH-4 measured knee pain using the WOMAC scale in participants with obesity-related osteoarthritis. At 9 mg, 75.8% of participants achieved clinically significant knee pain reduction, a 4.5-point improvement. At 12 mg, 74.3% achieved a 4.4-point reduction [1]. More striking: 12.0% of participants on retatrutide 12 mg were completely free of knee pain at 68 weeks, compared to 4.2% on placebo [1].

Retatrutide also produced measurable cardiovascular risk reductions. At 12 mg, systolic blood pressure fell by 14.0 mmHg [1]. Non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein (hsCRP) all declined [1]. These are downstream consequences of substantial weight loss and suggest the metabolic benefits extend beyond body composition.

For tirzepatide, the 176-week SURMOUNT-4 data revealed a 94% reduction in progression to type 2 diabetes compared to placebo [3]. Nearly 99% of participants on tirzepatide remained diabetes-free at 176 weeks [3]. This long-term durability matters for patients with pre-diabetes, where the prevention trajectory shifts dramatically.

The Safety Picture: What the Data Shows

Efficacy without tolerability is an incomplete story. Retatrutide's TRIUMPH-4 results introduced a new safety signal not observed in Phase 2: dysesthesia. At 12 mg, 20.9% of participants reported dysesthesia, described as an abnormal sense of touch where normal sensations feel unusual or painful [2]. The rate was 8.8% at 9 mg. On placebo, 0.7% reported the same event [1][2]. This neurological signal emerged at higher doses in Phase 3 and was not present in the earlier retatrutide trial, making it a genuine unknown for prescribers and patients [2]. BMO Capital Markets noted the events did not appear to lead to study discontinuation [2], but the prevalence at the highest dose warrants scrutiny.

Gastrointestinal adverse events were common across all three drugs. Retatrutide 12 mg produced nausea in 43.2% of participants versus 10.7% on placebo, vomiting in 20.9% versus 0.0%, and diarrhea in 33.1% versus 13.4% [1]. These rates were dose-dependent and drove discontinuation in some participants.

Discontinuation rates due to adverse events were 12.2% at 9 mg and 18.2% at 12 mg for retatrutide [1]. Some discontinuations were attributed to perceived excessive weight loss, an unusual but clinically documented phenomenon where patients or physicians discontinued due to reaching weight loss levels felt to be outside a safe or expected range [1]. Semaglutide's STEP 1 discontinuation rate was 7.0% versus 3.1% on placebo [5].

The dysesthesia signal remains the most important new safety finding in this drug class in recent years. Retatrutide's risk-benefit calculation at 12 mg must account for it.

What This Means for Patients and Prescribers

This article summarizes published clinical trial data for informational purposes only. Individual treatment decisions should be made in consultation with a qualified healthcare provider who can assess personal medical history and current health status.

The tiered mechanism story suggests a clear hierarchy: more receptor targets produce more weight loss. That hierarchy exists in the data, but clinical decision-making is more complex.

Semaglutide has the longest safety track record, the broadest insurance coverage, and a deep evidence base spanning multiple large RCTs. For patients with obesity who are starting therapy and have no severe metabolic complications, it remains a reasonable first-line choice.

Tirzepatide offers meaningfully higher weight loss with a dual mechanism and a longer Phase 3 track record. The 176-week data demonstrating a 94% reduction in diabetes progression makes it particularly relevant for patients with pre-diabetes or significant metabolic dysfunction [3].

Retatrutide produces the highest weight loss observed in any GLP-1 trial to date. The 58.6% of participants achieving at least 25% body weight loss at 12 mg, and the 23.7% achieving at least 35%, represent categorically different outcomes from earlier drugs [1]. For patients with severe obesity or obesity-related complications such as knee osteoarthritis, these numbers are clinically transformative.

The dysesthesia risk requires careful monitoring and patient counseling. Retatrutide remains under evaluation in seven additional Phase 3 trials within the TRIUMPH program, expected to report by 2026 [1]. Head-to-head comparison data against tirzepatide is not yet available, making indirect comparison the only tool prescribers currently have [author's note].